JP2004533250A5 - - Google Patents

Download PDF

Info

Publication number
JP2004533250A5
JP2004533250A5 JP2002592975A JP2002592975A JP2004533250A5 JP 2004533250 A5 JP2004533250 A5 JP 2004533250A5 JP 2002592975 A JP2002592975 A JP 2002592975A JP 2002592975 A JP2002592975 A JP 2002592975A JP 2004533250 A5 JP2004533250 A5 JP 2004533250A5
Authority
JP
Japan
Prior art keywords
cell
cells
domain
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002592975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004533250A (ja
Filing date
Publication date
Priority claimed from GBGB0112687.9A external-priority patent/GB0112687D0/en
Application filed filed Critical
Publication of JP2004533250A publication Critical patent/JP2004533250A/ja
Publication of JP2004533250A5 publication Critical patent/JP2004533250A5/ja
Pending legal-status Critical Current

Links

JP2002592975A 2001-05-24 2002-05-21 分泌された細菌エフェクタータンパク質の薬学的使用 Pending JP2004533250A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0112687.9A GB0112687D0 (en) 2001-05-24 2001-05-24 Pharmaceutical use of secreted bacterial effector proteins
PCT/GB2002/002384 WO2002096467A2 (en) 2001-05-24 2002-05-21 Pharmaceutical use for secreted bacterial effector proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009202601A Division JP2009286794A (ja) 2001-05-24 2009-09-02 分泌された細菌エフェクタータンパク質の薬学的使用

Publications (2)

Publication Number Publication Date
JP2004533250A JP2004533250A (ja) 2004-11-04
JP2004533250A5 true JP2004533250A5 (https=) 2005-12-22

Family

ID=9915236

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002592975A Pending JP2004533250A (ja) 2001-05-24 2002-05-21 分泌された細菌エフェクタータンパク質の薬学的使用
JP2009202601A Pending JP2009286794A (ja) 2001-05-24 2009-09-02 分泌された細菌エフェクタータンパク質の薬学的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009202601A Pending JP2009286794A (ja) 2001-05-24 2009-09-02 分泌された細菌エフェクタータンパク質の薬学的使用

Country Status (8)

Country Link
US (1) US20040208889A1 (https=)
EP (1) EP1390400A2 (https=)
JP (2) JP2004533250A (https=)
CN (1) CN100439394C (https=)
AU (1) AU2002256803B2 (https=)
CA (1) CA2448963A1 (https=)
GB (1) GB0112687D0 (https=)
WO (1) WO2002096467A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US8012491B2 (en) * 1996-08-23 2011-09-06 Syntaxin, Ltd. Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
DE102004035606A1 (de) * 2004-07-22 2006-03-30 Biotecon Therapeutics Gmbh Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit
WO2006137836A2 (en) * 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
US20090092652A1 (en) * 2004-08-20 2009-04-09 Children's Medical Center Corporation Method for the inhibition of angiogenesis or cancer using protective antigen related molecules
US8092806B2 (en) * 2005-04-11 2012-01-10 Yeda Research And Development Co. Ltd. Chimeric proteins, their preparation and pharmaceutical compositions containing them
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK2550366T3 (en) * 2010-03-23 2014-12-15 Imba Inst Für Molekulare Biotechnologie Gmbh Methods for identifying inhibitors of the type III secretion system
US20130273092A1 (en) * 2010-10-22 2013-10-17 Trudeau Institute Uses of yersinia yope peptide, gene and subparts thereof as a plague vaccine component and assays for yersinia pestis-specific t cells
KR101895768B1 (ko) * 2011-06-01 2018-09-07 시아먼 유니버시티 디프테리아 독소 무독성 돌연변이 씨알엠197 또는 그의 단편을 포함하는 융합 단백질
US10633643B2 (en) * 2015-05-15 2020-04-28 Board Of Regents Of The University Of Nebraska Engineered Clostridium botulinum toxin adapted to deliver molecules into selected cells
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
WO2019147988A1 (en) * 2018-01-25 2019-08-01 Innate Biologics Llc Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
WO2022087856A1 (zh) * 2020-10-26 2022-05-05 南京吉芮康生物科技研究院有限公司 一种减毒沙门氏菌分泌表达rbd结构域蛋白的新型冠状病毒疫苗抗原递呈系统及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2498192A2 (fr) * 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
AU573529B2 (en) * 1982-05-12 1988-06-16 President And Fellows Of Harvard College Hybrid proteins
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
JP3523879B2 (ja) * 1994-05-31 2004-04-26 アレルガン インコーポレイテッド 輸送タンパク質用クロストリジウム属細菌毒素の修飾
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5972899A (en) * 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
SE9702191D0 (sv) * 1997-06-09 1997-06-09 Sven Pettersson Coposition and methods for the treatment of inflammatory dideases
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
AU7577600A (en) * 1999-09-13 2001-04-17 Cornell Research Foundation Inc. Delivering to eucaryotic cells bacterial proteins that are secreted via type iiisecretion systems

Similar Documents

Publication Publication Date Title
JP2004533250A5 (https=)
Kosikowska et al. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015)
KR102139844B1 (ko) 암 표적화 치료용 알부민-결합 아르기닌 데이미나제를 포함하는 약제학적 조성물
CN101675067B (zh) 肽组合物的修饰以提高稳定性和递送效率
CA2482598A1 (en) Peptide inhibitors of protein kinase c
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
CN101946001A (zh) 多肽-核酸结合物及其应用
Shin et al. Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity
JP2009286794A (ja) 分泌された細菌エフェクタータンパク質の薬学的使用
KR20210057072A (ko) 알파 코넥신 c-말단 펩타이드에 대한 나노 입자 제제 및 사용 방법
EP1523336B1 (en) Targeted agents for nerve regeneration
AU2002256803A1 (en) Pharmaceutical use for secreted bacterial effector proteins
BRPI1014631A2 (pt) peptídeos e seus usos.
WO2021046398A3 (en) Combination antiviral therapy for measles
JP2021525711A5 (https=)
Suk Choi et al. Cell penetrating peptides for tumor targeting
JP2016509997A (ja) 骨粗鬆症を抑制するための治療
Sarfaraz et al. Recent updates on peptide molecules in drug and vaccine development
ES2682679T3 (es) Supresión del picor
EP3166406B1 (en) Cytokine-chitosan bioconjugates and methods of using the same
MX2022002293A (es) Péptidos recombinantes inmunotolerantes similares a la elastina y métodos de uso.
WO2014020209A1 (es) Uso de hidrolizados de proteínas lácteas como protectores a nivel gastrointestinal
Fabbri et al. Bacterial protein toxins: current and potential clinical use
JP2003513941A (ja) 溶菌毒素および毒素結合体の使用
US20050256040A1 (en) Artificially designed pore-forming proteins with anti-tumor effects